Deep learning identifies TP-41 for methylglyoxal scavenging in Alzheimer's treatment
Theranostics · 2026
DOI: 10.7150/thno.111550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Aron Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon, 2199…. Hauptthemen laut MEDLINE: Alzheimer Disease, Pyruvaldehyde, Deep Learning. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Rationale
Increased levels of advanced glycation end products (AGEs) have been observed in the brain tissues of patients with Alzheimer's disease (AD). Methylglyoxal (MGO) is a potent precursor of AGEs. To date, there have been no reports of utilizing deep learning (DL) technologies to target MGO scavengers for the development of AD therapeutics. Therefore, DL-driven approaches may play a crucial role in identifying potential MGO scavengers and candidates for Alzheimer's treatment.
Methods
We developed "DeepMGO," a novel DL-based MGO scavenging activity prediction model, trained on 2,262 MGO scavenging activity assays from 660 compounds. Using this approach, we identified and validated TP-41 as a potential MGO scavenger in a mouse model of memory impairment.
Results
DeepMGO demonstrated robust predictive performance and identified novel compounds with high MGO scavenging activity. TP-41 ameliorated depression symptoms and memory deficits in mouse models.
Conclusions
Using DeepMGO, we identified TP-41 as a potential therapeutic agent for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon, 21999, Korea.
- Division of Food Science and Technology, Gyeongsang National University, Jinju, Gyeongnam 52828, Korea.
- Department of Genome Medicine and Science, Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, 21565, Korea.
- College of Pharmacy and Gachon Institute of Pharmaceutical Science, Gachon University, 191, Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Korea.
- Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
- MetaCen Therapeutics Company, Changnyong-daero 256 Beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do 16229, Korea.
Zitieren
APA
Park, A., Hong, S. M., Lee, Y., Lee, J., Jeon, S., Seo, S. Y., Lee, J., Kim, S. H., Ko, E. J., Lee, H. R., Jung, S. H., Bae, M., Kang, M. C., Park, M. G., Nam, S., & Kim, S. Y. (2026). Deep learning identifies TP-41 for methylglyoxal scavenging in Alzheimer's treatment. Theranostics. https://doi.org/10.7150/thno.111550
Vancouver
Park A, Hong SM, Lee Y, Lee J, Jeon S, Seo SY, et al. Deep learning identifies TP-41 for methylglyoxal scavenging in Alzheimer's treatment. Theranostics. 2026. doi:10.7150/thno.111550
BibTeX
@article{Park2026,
author = {Park, Aron and Hong, Seong-Min and Lee, Yeeun and Lee, Jungeun and Jeon, Seunggyu and Seo, Seung-Yong and Lee, Jinhyuk and Kim, Seon-Hyeok and Ko, Eun Ji and Lee, Hae Ran and Jung, Sang Heon and Bae, Munhyung and Kang, Min Cheol and Park, Myoung Gyu and Nam, Seungyoon and Kim, Sun Yeou},
title = {Deep learning identifies TP-41 for methylglyoxal scavenging in Alzheimer's treatment},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.111550}
}
EUVIMED